News

Video

Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA Study

Author(s):

Alexander Spira, MD, PhD, FACP

A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.

Related Videos
Alec Watson, MD
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
RMC-9805
LGSOC 2024
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Related Content
Non–Small Cell Lung cancer | Image Credit: © Axel Kock – stock.adobe.com
December 21st 2024

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
December 20th 2024

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Lung Cancer
December 17th 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC

FDA
December 17th 2024

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC